William Blair Has Optimistic Outlook of TERN FY2025 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Equities researchers at William Blair boosted their FY2025 EPS estimates for shares of Terns Pharmaceuticals in a note issued to investors on Tuesday, November 11th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of ($1.08) per share for the year, up from their previous estimate of ($1.09). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share. William Blair also issued estimates for Terns Pharmaceuticals’ Q2 2026 earnings at ($0.30) EPS, FY2026 earnings at ($1.21) EPS and FY2027 earnings at ($1.37) EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Terns Pharmaceuticals in a report on Wednesday, October 8th. Truist Financial reissued a “buy” rating and set a $28.00 price target (up from $20.00) on shares of Terns Pharmaceuticals in a research note on Tuesday, November 4th. Mizuho upped their price objective on Terns Pharmaceuticals from $9.00 to $32.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Wall Street Zen upgraded shares of Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Finally, HC Wainwright raised shares of Terns Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.50.

Terns Pharmaceuticals Stock Performance

Shares of TERN opened at $20.30 on Thursday. Terns Pharmaceuticals has a 52 week low of $1.87 and a 52 week high of $21.12. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -19.71 and a beta of -0.02. The stock has a fifty day moving average of $9.54 and a 200-day moving average of $6.37.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its earnings results on Monday, November 10th. The company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.03.

Institutional Investors Weigh In On Terns Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Engineers Gate Manager LP bought a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth approximately $41,000. Canada Pension Plan Investment Board bought a new stake in Terns Pharmaceuticals during the second quarter worth $46,000. LeConte Wealth Management LLC bought a new stake in shares of Terns Pharmaceuticals in the 2nd quarter worth $47,000. Dynamic Technology Lab Private Ltd purchased a new stake in Terns Pharmaceuticals in the 1st quarter valued at about $51,000. Finally, Velan Capital Investment Management LP increased its position in shares of Terns Pharmaceuticals by 17.6% during the second quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock valued at $75,000 after acquiring an additional 3,000 shares during the last quarter. Institutional investors own 98.26% of the company’s stock.

Insider Buying and Selling at Terns Pharmaceuticals

In related news, Director Jill M. Quigley sold 24,520 shares of Terns Pharmaceuticals stock in a transaction on Tuesday, November 4th. The shares were sold at an average price of $18.00, for a total transaction of $441,360.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is currently owned by company insiders.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.